9 recruiting, 2 active not recruiting, 2 completed, 2 not yet recruiting. 8 Phase 2, 3 Not applicable, 3 Phase 1, 2 Phase 3.
Follow Prostate CA: new trials by email Literature Review of Prostate CA trials Research Report on Prostate CA
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Prostate MRI Analysis by Radiologists and Artificial Intelligence - Disease Identification and Guided Management AI (Lucida Pi) interpretation, Radiologist interpretation - Prostate CA | Not applicable | Not yet recruiting | University College, London | 500 | 2026-10-01 | 2026-06-30 |
| Trans and Non-binary Prostate-Specific Antigen Reference Interval Determination Study Prostate CA | Recruiting | Queen Mary University of London | 500 | 2026-04-04 | 2026-06-04 | |
| Fezolinetant for Treating Hot Flashes in Men With Prostate Cancer Fezolinetant - Prostate CA, Androgen Deprivation Therapy | Phase 2 | Recruiting | University of Vermont | 32 | 2025-12-18 | 2026-02-05 |
| Patient Empowerment Via Mobile Health Applications (MHAs) Digital health application engagement and empowerment - Empowerment, Patient, Mobile Application | Enrolling by invitation | Constantinos Zamboglou | 50 | 2025-10-15 | 2026-09-18 | |
| Phase II Randomized Trial of 2 Versus 5 Fraction Prostate Stereotactic Ablative Radiotherapy for Intermediate Risk Prostate Cancer Stereotactic Body Radiation Therapy (SBRT) - Prostate CA | Phase 2 | Recruiting | British Columbia Cancer Agency | 100 | 2025-09-04 | 2026-06-24 |
| Research on the Application of 68Ga-PSMA-CYC PET Imaging in the Diagnosis, Staging, and Restaging of Prostate Cancer 68Ga-PSMA-CYC, CYC - Prostate CA | Phase 1 / Phase 2 | Recruiting | First Affiliated Hospital of Fujian Medical University | 40 | 2025-05-15 | 2025-07-09 |
| Ultralow Dose PET Imaging for PSMA Expression Piflufolastat F18 - Healthy Volunteer, Prostate CA | Phase 2 | Recruiting | Akiva Mintz | 200 | 2025-05-12 | 2025-06-04 |
| Clinical Study on Neoadjuvant Therapy of Homoharringtonine Combined With Androgen Deprivation for Prostate Cancer Homoharringtonine combined with androgen deprivation therapy, Placebo combined with androgen deprivation treatment group, radical prostatectomy - Prostate CA | Phase 2 | Recruiting | baotai Liang | 96 | 2025-03-19 | 2025-09-08 |
| Clinical Study of Geranium Wilfordii Combined With Androgen Deprivation in Neoadjuvant Therapy of Prostate Cancer Geranium wilfordii combined with androgen deprivation treatment, Androgen deprivation treatment, radical prostatectomy - Prostate CA | Phase 2 / Phase 3 | Not yet recruiting | baotai Liang | 95 | 2025-03-10 | 2025-03-06 |
| Prostate Cancer Care Disparity Analysis Project (ProGAP) No Intervention: Observational Cohort - Prostate CA | Unknown | Ankara University | 400 | 2025-03-10 | 2025-07-24 | |
| Clinical Study of Fasudil Hydrochloride and PD1 Inhibitor Combined With Androgen Deprivation in Neoadjuvant Therapy of Prostate Cancer Fasudil hydrochloride and PD1 inhibitor combined with androgen deprivation therapy, Placebo combined with androgen deprivation therapy, radical prostatectomy - Prostate CA | Phase 2 / Phase 3 | Recruiting | baotai Liang | 83 | 2025-02-16 | 2025-11-18 |
| A Randomized Controlled Trial to Improve the Therapeutic Effect of Robot-assisted Radical Prostatectomy (RARP) Using Indocyanine Green Fluorescence Imaging In robot-assisted radical prostatectomy, indocyanine green fluorescent solution is injected through the urethra, and the position and structure of the urethra are observed by the device - Prostate CA | Active not recruiting | Liu Cheng | 50 | 2024-11-26 | 2024-12-27 | |
| Neoadjuvant Darolutamide and Relugolix Combination Preceding Radical Prostatectomy for Prostate Cancer Darolutamide, Relugolix, Radical Prostatectomy - Prostate CA, Prostate Cancer (Adenocarcinoma) | Phase 1 | Active not recruiting | AdventHealth | 32 | 2024-10-22 | 2026-11-10 |
| FK-PC101 as Adjuvant Therapy for Men With High-Risk Prostate Cancer FK-PC101, Standard of Care (SOC) - Prostate Cancer (Adenocarcinoma), Prostate CA | Phase 2 | Recruiting | Cellvax Therapeutics Inc | 100 | 2024-10-14 | 2024-10-21 |
| Research on PSMA-Targeted Intraoperative Fluorescent Imaging Agents 0.01mg/kg DGPR1008 Injection Dose Group 1 (n=6), 0.02mg/kg DGPR1008 Injection Dose Group 2 (n=6), 0.04mg/kg DGPR1008 Injection Dose Group 3 (n=6) - Prostate Cancer Patients Undergoing Radical Prostatectomy, Prostate CA | Phase 1 | Completed | Haitao Niu, MD | 32 | 2024-06-24 | 2025-08-03 |
| Evaluation of the Performance of a Novel Prostate Biopsy System Compared With Standard of Care Biopsy Needle on Quantitative and Qualitative Tissue Parameters Prostate biopsy needle - Prostate Disease, Prostate CA | Not applicable | Recruiting | Uro-1 Medical | 200 | 2022-08-01 | 2025-05-07 |
| Evaluation of Addition of Dexamethasone to Transversus Abdominis Plane (TAP) Peripheral Nerve Block Dexamethasone, TAP block - Prostate CA | Not applicable | Completed | Steward St. Elizabeth's Medical Center of Boston, Inc. | 24 | 2010-12-01 | 2018-09-21 |
Prostatic Neoplasms (7) · Adenocarcinoma (2) · Hot Flashes (1) · Neoplasms (1) · Patient Participation (1) · Prostatic Diseases (1)
Genital Diseases (8) · Genital Diseases, Male (8) · Male Urogenital Diseases (8) · Urogenital Diseases (8) · Genital Neoplasms, Male (7) · Neoplasms (7) · Neoplasms by Site (7) · Prostatic Diseases (7) · Urogenital Neoplasms (7) · Carcinoma (2) · Neoplasms by Histologic Type (2) · Neoplasms, Glandular and Epithelial (2) · Behavior (1) · Health Behavior (1) · Pathological Conditions, Signs and Symptoms (1)
Androgen Antagonists (2) · 2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid (1) · Blood Specimen Collection (1) · Dexamethasone (1) · Magnetic Resonance Spectroscopy (1) · Radiosurgery (1) · Standard of Care (1) · Surgical Procedures, Operative (1) · darolutamide (1) · fasudil (1) · fezolinetant (1) · relugolix (1)
baotai Liang (3) · AdventHealth (1) · Akiva Mintz (1) · Ankara University (1) · British Columbia Cancer Agency (1) · Cellvax Therapeutics Inc (1) · Constantinos Zamboglou (1) · First Affiliated Hospital of Fujian Medical University (1) · Haitao Niu, MD (1) · Liu Cheng (1) · Queen Mary University of London (1) · Steward St. Elizabeth's Medical Center of Boston, Inc. (1) · University College, London (1) · University of Vermont (1) · Uro-1 Medical (1)
United States (6) · China (5) · Canada (1) · Cyprus (1) · Turkey (Türkiye) (1) · United Kingdom (1)
Abraham Alexander (1) · Andrew Sternlicht, MD (1) · Deborah Mukherji (1) · Doug Pendse, MB ChB MD (Res) MRCS FRCR (1) · Fernando Kreutz, MD PhD (1) · Luis Castelo Branco (1) · Mohammed Shahait (1) · Thomas Lawson, PhD (1) · Veeru Kasivisvanathan, MBBS BSc FRCS MSc PGCert PhD (1) · Weibing Miao, MD (1) · Winkle Kwan (1)